November 20, 2002
Synthetics Replacing Degenerative Discs at Double-Digit Rates; Nanotech Drug Delivery Gearing Up for Growth, According to MedMarket Diligence
FOOTHILL RANCH, Calif., November 20 /PRNewswire/ -- High growth potential is projected for spinal disc replacement products, already growing at rates in excess of 25%, according to the November issue of “MedMarkets,” a publication of MedMarket Diligence, LLC.
“One factor driving this growth is technology currently in development that could soon impact the market for degenerative disc products in much the same way that arthroplasty has impacted the hip and knee repair market, “ said Patrick J. Driscoll, publisher of “MedMarkets.”
“This market is expected to grow much more quickly than other related markets,” he continued. New products currently in the pipeline will begin the hit the market over the next five years, creating a more than $1 billion U.S. market by 2007.
Key companies involved in developing products that address degenerative disc disease include: Raymedica, Stryker, SpineWave, Disc Dynamics, Anulex, Medtronic Sofamor Danek, DePuy Acromed, Link Spinal Group and Spine Solutions.
Another medical products market expected to see strong growth is that for nanoparticles. The November issue of MedMarkets analyzes the development of nanoparticles for use in targeted drug delivery. This area comprises one of the more successful medical applications being developed with nanotechnology. “What was once a futuristic idea is becoming real as several companies have developed real-world applications and are expected to enter the marketplace soon,” said Driscoll.
Drug delivery technologies are being developed around nanotechnology areas such as cyclic peptides, quantum dots, liposomes, dendrimers, and nanoparticulate bacteriocides. Companies discussed in the “MedMarkets” article, which are only a few of the many companies working in this area, include MicroCHIPS/Micralyne, ALZA/Johnson & Johnson, Acusphere, BioDelivery Sciences International, Flamel Technologies, iMEDD, NanoBio, NanoScale Materials, OraPharma, Targesome, Evident Technologies and Dow Corporation.
“MedMarkets,” published by MedMarket Diligence, analyzes the market and clinical practice implications of developments in medical technology--medical devices, equipment and supplies as well as biomaterials, biotech, pharmaceutical, e-health and others. In addition, the company publishes dedicated market/technology reports, and is developing other information solutions.
For more information on “MedMarkets,” the MedMarket Diligence report on nanotechnology/MEMS or other strategic studies produced by MedMarket Diligence, LLC, contact Patrick Driscoll at (949) 859-3401, or e-mail,. In addition, a sample issue of “MedMarkets” and additional information on other MedMarket Diligence products can be found on the Web site at http://www.mediligence.com.